Prostate Cancer
Conditions
Brief summary
The assessment of biochemical failure ratio.
Detailed description
Biochemical Progression Free Survival - time of survival from the end of 177Lu-PSMA treatment to biochemical progression or death., Radiological Progression Free Survival - time of survival from the end of 177Lu-PSMA treatment to the radiological progression defined accoring to the PCWG3 criteria or death., Time from the end of 177Lu-PSMA treatment to inclusion of other therapeutic intervention., Frequency and count of Patients with adverse events., The comparison of quality of life ratios (EORTC QLQ-PR25) between study groups.
Interventions
Sponsors
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The assessment of biochemical failure ratio. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical Progression Free Survival - time of survival from the end of 177Lu-PSMA treatment to biochemical progression or death., Radiological Progression Free Survival - time of survival from the end of 177Lu-PSMA treatment to the radiological progression defined accoring to the PCWG3 criteria or death., Time from the end of 177Lu-PSMA treatment to inclusion of other therapeutic intervention., Frequency and count of Patients with adverse events., The comparison of quality of life ratios (EORTC QLQ-PR25) between study groups. | — |
Countries
Poland
Outcome results
None listed